However, in releasing the longer-lasting and more effective Wegovy, Novo's Saxenda has dwindled in market share, with analysts at GlobalData, parent company of Pharmaceutical Technology , forecasting that the drug's sales will plummet to just $135m in 2031 down 91% from $1.5bn peak sales in 2022
Acta Sci Pol Technol Aliment (2021) 20:37581
[DOI] [PMC free article] [PubMed] [Google Scholar] 61.Ruoslahti E, Pierschbacher MD
The new, expanded Zepbound approval means that insurance providers, including Medicare, will likely cover the medication for people with sleep apnea and obesity
Patients often come to us with a critical question: How much weight can I really expect to lose? The answer, as with any medical treatment, is not a simple number
If you are experiencing rectal bleeding, you and your healthcare provider will want to know why it is happening and what to do about it